这些问题都在瑞士的托马斯·鲍姆加特纳和乌尔斯·菲施巴赫一项令人振奋的新研究中得到了阐述。

All these questions are addressed in an exciting new study performed in Switzerland and led by Thomas Baumgartner and Urs Fischbacher.

youdao

帕斯特纳克先生说生物仿制制药威胁到了现有的生物技术制药公司，如安进公司和基因泰克公司(现在已属瑞士制药巨头罗氏旗下)，他们的数十亿美元的销售目标现在都有风险。

Biosimilars threaten incumbent biotech firms such as Amgen and Genentech (now part of Roche, a Swiss drugs giant), which have billions of dollars of sales at risk, argues Mr Pasternak.

youdao